ONYX PHARMA - Carfilzomib Approval - Now or Later?
Future growth remains tied to the Approval of Carfilzomib (PhIIb, next-generation proteasome inhibitor, Relapsed and Refractory Multiple Myeloma - R/R MM). Delay could limit the potential of Carfilzomib, as generic Takeda’s Velcade (L, MM – first and second-line, MCL) might become available from 2017 coupled with probable approval of Celgene’s Pomalidimide (PhII, RR MM). There are two registration PhIII trials underway – ASPIRE (International) and FOCUS (EU), and interim data from these studies are expected to be out only in 1H13. Moreover, Bayer settled its litigation with ONXX... For more details, please read our report, released on Nov. 8, 2011 on “Onyx Pharma - Carfilzomib Approval – Now or Later?”
COMPANIES MENTIONED
ONYX
ONYX
More Publications
Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!
US$ 90.00
March 2012
4 pages
Onyx Pharma – Kyprolis to Accelerate Growth
US$ 140.00
June 2012
4 pages
Onyx Pharma - ASCO ’12: Kyprolis’ Data enough to obtain an ‘Accelerate Approval’?
US$ 90.00
May 2012
4 pages
Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement
US$ 90.00
November 2011
6 pages
ONYX PHARMA - Testing Time Ahead in the Hematological Cancer Space
US$ 140.00
September 2011
3 pages
